Allen P Kaplan

List of Publications by Year
in descending order

141 papers	10,678 citations	30070 54 h-index	33894 99 g-index
244 all docs	244 docs citations	244 times ranked	5060 citing authors

#	Article	IF	Citations
1	gC1qR Antibody Can Modulate Endothelial Cell Permeability in Angioedema. Inflammation, 2022, 45, 116-128.	3.8	3
2	The international EAACI/GAÂ²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 734-766.	5.7	392
3	Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 716-722.	3.8	14
4	The international WAO/EAACI guideline for the management of hereditary angioedemaâ€"The 2021 revision and update. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1961-1990.	5.7	153
5	The international WAO/EAACI guideline for the management of hereditary angioedema â€“ The 2021 revision and update. World Allergy Organization Journal, 2022, 15, 100627.	3.5	37
6	Bradykinin formation by mutant plasminogen. Blood, 2022, 139, 2732-2733.	1.4	0
7	Pathways for bradykinin formation and interrelationship with complement as a cause of edematous lung in COVID-19 patients. Journal of Allergy and Clinical Immunology, 2021, 147, 507-509.	2.9	16
8	Biologics for the Use in Chronic Spontaneous Urticaria: When and Which. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1067-1078.	3.8	61
9	Blood Clotting and the Pathogenesis of Types I and II Hereditary Angioedema. Clinical Reviews in Allergy and Immunology, 2021, 60, 348-356.	6.5	17
10	The Pathogenesis of Chronic Spontaneous Urticaria: The Role of Infiltrating Cells. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2195-2208.	3.8	61
11	Analysis of cold activation of the contact system in hereditary angioedema with normal C1 inhibitor. Molecular Immunology, 2021, 136, 150-160.	2.2	2
12	SARS-CoV-2 Exacerbates COVID-19 Pathology Through Activation of the Complement and Kinin Systems. Frontiers in Immunology, 2021, 12, 767347.	4.8	28
13	C1 Inhibitor Activity and Angioedema Attacks in Patients with Hereditary Angioedema. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 892-900.	3.8	12
14	International Consensus on the Use of Genetics in the Management of Hereditary Angioedema. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 901-911.	3.8	43
15	Diagnosis and treatment of chronic spontaneous urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1830-1832.	5.7	6
16	Preventing anaphylaxis fatalities: Should we target bradykinin?. Journal of Allergy and Clinical Immunology, 2020, 145, 1365-1366.	2.9	7
17	sgp120 and the contact system in hereditary angioedema: A diagnostic tool in HAE with normal C1 inhibitor. Molecular Immunology, 2020, 119, 27-34.	2.2	8
18	Definition, aims, and implementation of GA²LEN/HAEi Angioedema Centers of Reference and Excellence. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2115-2123.	5.7	29

#	Article	IF	Citations
19	Protease activity in single-chain prekallikrein. Blood, 2020, 135, 558-567.	1.4	22
20	Nomenclature of factor XI and the contact system. Journal of Thrombosis and Haemostasis, 2019, 17, 2216-2219.	3.8	11
21	Latin American chronic urticaria registry (CUR) contribution to the understanding and knowledge of the disease in the region. World Allergy Organization Journal, 2019, 12, 100042.	3.5	6
22	Basophil histamine release in patients with chronic spontaneous urticaria: Optimize or minimize. Journal of Allergy and Clinical Immunology, 2019, 144, 622-623.	2.9	4
23	Treatment of urticaria: a clinical and mechanistic approach. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 387-392.	2.3	10
24	A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide. Diabetes Therapy, 2019, 10, 21-33.	2.5	10
25	Angioedema and Shear Stress Modulate Endothelial Permeability Through gC1qR. FASEB Journal, 2019, 33, 542.15.	0.5	1
26	The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria. Journal of Allergy and Clinical Immunology, 2018, 141, 1138-1139.e7.	2.9	64
27	Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study. Journal of the American Academy of Dermatology, 2018, 78, 793-795.	1.2	13
28	Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. International Journal of Cardiology, 2018, 264, 118-123.	1.7	27
29	Chronic Spontaneous Urticaria: The Devil's Itch. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1097-1106.	3.8	75
30	Diagnosis, pathogenesis, and treatment of chronic spontaneous urticaria. Allergy and Asthma Proceedings, 2018, 39, 184-190.	2.2	21
31	Importance of angioedema-free days in patients with chronic idiopathic or spontaneous urticaria. Annals of Allergy, Asthma and Immunology, 2017, 118, 524.	1.0	1
32	Reply. Journal of Allergy and Clinical Immunology, 2017, 139, 1720-1721.	2.9	4
33	Pathogenesis of Hereditary Angioedema. Immunology and Allergy Clinics of North America, 2017, 37, 513-525.	1.9	78
34	Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema. Journal of Allergy and Clinical Immunology, 2017, 140, 170-176.	2.9	34
35	Chronic Spontaneous Urticaria: Pathogenesis and Treatment Considerations. Allergy, Asthma and Immunology Research, 2017, 9, 477.	2.9	36
36	The Search for Biomarkers in Hereditary Angioedema. Frontiers in Medicine, 2017, 4, 206.	2.6	43

#	Article	IF	Citations
37	Fibrinolysis and bradykinin formation: From inÂvitro observations to human disease in â€œjustâ€•45Âyears. Journal of Allergy and Clinical Immunology, 2016, 138, 1424-1425.	2.9	0
38	Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies. Annals of Allergy, Asthma and Immunology, 2016, 117, 370-377.e1.	1.0	26
39	The complement and contact activation systems: partnership in pathogenesis beyond angioedema. Immunological Reviews, 2016, 274, 281-289.	6.0	41
40	Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent. Clinical Reviews in Allergy and Immunology, 2016, 51, 207-215.	6.5	41
41	Cytokine and Estrogen Stimulation of Endothelial Cells Augments Activation of the Surface-Bound Prekallikrein-High Molecular Weight Kininogen Complex: Implications for Hereditary Angioedema (HAE). Journal of Allergy and Clinical Immunology, 2016, 137, AB249.	2.9	3
42	Rapid oral desensitization to sirolimus in a patient with lymphangioleiomyomatosis. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 352-353.	3.8	7
43	Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels. Journal of Allergy and Clinical Immunology, 2016, 137, 1822-1829.e1.	2.9	38
44	Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. Journal of Allergy and Clinical Immunology, 2016, 137, 474-481.	2.9	141
45	In vitro comparison of bradykinin degradation by aliskiren, a renin inhibitor, and an inhibitor of angiotensin-converting enzyme. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 321-327.	1.7	8
46	How omalizumab came to be studied as a therapy for chronic spontaneous/idiopathic urticaria. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 648.	3.8	7
47	Neurotropin promotes NGF signaling through interaction of GM1 ganglioside with Trk neurotrophin receptor in PC12 cells. Brain Research, 2015, 1596, 13-21.	2.2	28
48	Bradykinin-Mediated Diseases. Chemical Immunology and Allergy, 2014, 100, 140-147.	1.7	18
49	The Bradykinin-Forming Cascade: A Historical Perspective. Chemical Immunology and Allergy, 2014, 100, 205-213.	1.7	16
50	Biologic agents and the therapy of chronic spontaneous urticaria. Current Opinion in Allergy and Clinical Immunology, 2014, 14, 347-353.	2.3	9
51	Therapy of chronic urticaria: a simple, modern approach. Annals of Allergy, Asthma and Immunology, 2014, 112, 419-425.	1.0	43
52	Pathogenic Mechanisms of Bradykinin Mediated Diseases. Advances in Immunology, 2014, 121, 41-89.	2.2	109
53	The thrombogenicity of C1 esterase inhibitor (human): Review of the evidence. Allergy and Asthma Proceedings, 2014, 35, 444-453.	2.2	31
54	Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria. New England Journal of Medicine, 2013, 368, 924-935.	27.0	838

#	Article	IF	Citations
55	Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. Journal of Allergy and Clinical Immunology, 2013, 132, 101-109.	2.9	461
56	Factor XIIâ€“independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II. Journal of Allergy and Clinical Immunology, 2013, 132, 470-475.	2.9	46
57	Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment. PLoS ONE, 2013, 8, e53773.	2.5	113
58	Hereditary angioedema with normal C1 inhibitor function: Consensus of an international expert panel. Allergy and Asthma Proceedings, 2012, 33, 145-156.	2.2	142
59	Diagnosis and Treatment of Urticaria and Angioedema: A Worldwide Perspective. World Allergy Organization Journal, 2012, 5, 125-147.	3.5	150
60	Type III hereditary angioedema: defined, but not understood. Annals of Allergy, Asthma and Immunology, 2012, 109, 153-154.	1.0	10
61	Treatment of Chronic Spontaneous Urticaria. Allergy, Asthma and Immunology Research, 2012, 4, 326.	2.9	88
62	Biologic Agents in the Treatment of Urticaria. Current Allergy and Asthma Reports, 2012, 12, 288-291.	5.3	7
63	Bradykinin and the Pathogenesis of Hereditary Angioedema. World Allergy Organization Journal, 2011, 4, 73-75.	3.5	27
64	Omalizumab is effective in nonautoimmune urticaria. Journal of Allergy and Clinical Immunology, 2011, 127, 1300-1302.	2.9	60
65	A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamineâ€“refractory chronic idiopathic urticaria. Journal of Allergy and Clinical Immunology, 2011, 128, 567-573.e1.	2.9	332
66	Structure?Function Studies Using Deletion Mutants Identify Domains of gC1qR/p33 as Potential Therapeutic Targets for Vascular Permeability and Inflammation. Frontiers in Immunology, 2011, 2, .	4.8	21
67	What to Do With Refractory Urticaria Patients. Current Allergy and Asthma Reports, 2011, 11, 189-191.	5.3	2
68	Treatment of Cold Urticaria. Current Allergy and Asthma Reports, 2010, 10, 223-224.	5.3	2
69	Dietary Therapy for Chronic Urticaria. Current Allergy and Asthma Reports, 2010, 10, 225-226.	5.3	0
70	Kinins, Airway Obstruction, and Anaphylaxis. Chemical Immunology and Allergy, 2010, 95, 67-84.	1.7	11
71	Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis. Annals of Allergy, Asthma and Immunology, 2010, 104, 50-54.	1.0	26
72	The bradykinin-forming cascade and its role in hereditary angioedema. Annals of Allergy, Asthma and Immunology, 2010, 104, 193-204.	1.0	134

#	Article	IF	Citations
73	Enzymatic pathways in the pathogenesis of hereditary angioedema: The role of C1 inhibitor therapy. Journal of Allergy and Clinical Immunology, 2010, 126, 918-925.	2.9	98
74	The plasma bradykinin-forming pathways and its interrelationships with complement. Molecular Immunology, 2010, 47, 2161-2169.	2.2	161
75	Methotrexate for moderate to severe adult atopic eczema. Current Allergy and Asthma Reports, 2009, 9, 260-261.	5.3	0
76	Mycophenolate mofetil for severe childhood atopic dermatitis. Current Allergy and Asthma Reports, 2009, 9, 262-262.	5.3	0
77	What the first 10,000 patients with chronic urticaria have taught me: A personal journey. Journal of Allergy and Clinical Immunology, 2009, 123, 713-717.	2.9	38
78	Factor XIIâ€“independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor. Journal of Allergy and Clinical Immunology, 2009, 124, 143-149.	2.9	49
79	Angioedema in the Emergency Department. , 2009, , 335-348.		1
80	Urticaria and Angioedema. , 2009, , 1063-1081.		10
81	Treatment of chronic autoimmune urticaria with omalizumab. Journal of Allergy and Clinical Immunology, 2008, 122, 569-573.	2.9	240
82	Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. Annals of Allergy, Asthma and Immunology, 2008, 101, 279-286.	1.0	42
83	Angioedema. World Allergy Organization Journal, 2008, 1, 103-113.	3.5	88
84	Basophil secretion in chronic urticaria: Autoantibody-dependent or not?. Journal of Allergy and Clinical Immunology, 2007, 120, 729-730.	2.9	19
85	Assembly, activation, and signaling by kinin-forming proteins on human vascular smooth muscle cells. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H251-H257.	3.2	34
86	A new mechanism for immunologic initiation of asthma. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 1267-1268.	7.1	5
87	Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. Journal of Allergy and Clinical Immunology, 2005, 115, 815-821.	2.9	93
88	Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Annals of Allergy, Asthma and Immunology, 2005, 94, 662-669.	1.0	47
89	Angioedema. Journal of the American Academy of Dermatology, 2005, 53, 373-388.	1.2	294
90	Does C-2 kinin exist?. Journal of Allergy and Clinical Immunology, 2005, 115, 876.	2.9	9

#	Article	IF	Citations
91	Formation of Bradykinin: A Major Contributor to the Innate Inflammatory Response. Advances in Immunology, 2005, 86, 159-208.	2.2	115
92	Interaction of high molecular weight kininogen binding proteins on endothelial cells. Thrombosis and Haemostasis, 2004, 91, 61-70.	3.4	55
93	Chronic urticaria: Pathogenesis and treatmentâ˜†â˜†â˜†.... Journal of Allergy and Clinical Immunology, 2004, 114, 465-474.	2.9	302
94	Antithyroid antibodies in chronic urticaria and angioedema. Journal of Allergy and Clinical Immunology, 2003, 112, 218.	2.9	96
95	High molecular weight kininogen and factor XII binding to endothelial cells and astrocytes. Thrombosis and Haemostasis, 2003, 90, 787-795.	3.4	29
96	Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 896-900.	7.1	145
97	A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. Journal of Allergy and Clinical Immunology, 2002, 109, 114-118.	2.9	166
98	Pathways for bradykinin formation and inflammatory disease. Journal of Allergy and Clinical Immunology, 2002, 109, 195-209.	2.9	262
99	TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: Comparison with the allergen-induced late-phase cutaneous reaction. Journal of Allergy and Clinical Immunology, 2002, 109, 694-700.	2.9	244
100	Chronic Urticaria and Angioedema. New England Journal of Medicine, 2002, 346, 175-179.	27.0	333
101	Secretion of Cytokines, Histamine and Leukotrienes in Chronic Urticaria. International Archives of Allergy and Immunology, 2002, 129, 254-260.	2.1	68
102	Inhibition of contact activation by a kininogen peptide (HKH20) derived from domain 5. International Immunopharmacology, 2002, 2, 1875-1885.	3.8	11
103	Activation of the bradykinin-forming cascade on endothelial cells: a role for heat shock protein 90. International Immunopharmacology, 2002, 2, 1851-1859.	3.8	33
104	Chronic urticariaâ€"new concepts regarding pathogenesis and treatment. Current Allergy and Asthma Reports, 2002, 2, 263-264.	5.3	8
105	Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or TH2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. Journal of Allergy and Clinical Immunology, 2001, 108, 394-401.	2.9	59
106	Mechanisms of autoimmune activation of basophils in chronic urticaria. Journal of Allergy and Clinical Immunology, 2001, 107, 1056-1062.	2.9	178
107	Factor XII-dependent Contact Activation on Endothelial Cells and Binding Proteins gC1qR and Cytokeratin 1. Thrombosis and Haemostasis, 2001, 85, 119-124.	3.4	55
108	Chemokines, Chemokine Receptors and Allergy. International Archives of Allergy and Immunology, 2001, 124, 423-431.	2.1	119

#	Article	IF	Citations
109	Activation of the Plasma Kinin Forming Cascade along Cell Surfaces. International Archives of Allergy and Immunology, 2001, 124, 339-342.	2.1	7
110	Activation of the Kinin-Forming Cascade on the Surface of Endothelial Cells. Biological Chemistry, 2001, 382, 71-5.	2.5	41
111	Platelet Glycoprotein Ib: A Zinc-Dependent Binding Protein for the Heavy Chain of High-Molecular-Weight Kininogen. Molecular Medicine, 1999, 5, 555-563.	4.4	41
112	Interaction of Factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated AÎ² protein of Alzheimer's disease. Immunopharmacology, 1999, 43, 203-210.	2.0	35
113	Cytokeratin 1 and gC1qR Mediate High Molecular Weight Kininogen Binding to Endothelial Cells. Clinical Immunology, 1999, 92, 246-255.	3.2	74
114	A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticariaâ˜†â˜†â˜†â˜…... Journal of Allergy and Clinical Immunology, 1999, 104, 1071-1078.	2.9	152
115	Complement dependence of histamine release in chronic urticariaâ˜†â˜†â˜†. Journal of Allergy and Clinical Immunology, 1999, 104, 169-172.	2.9	164
116	Zinc-Dependent Activation of the Plasma Kinin-Forming Cascade by Aggregated Î² Amyloid Protein. Clinical Immunology, 1999, 90, 89-99.	3.2	55
117	The kinin system. Clinical Reviews in Allergy and Immunology, 1998, 16, 335-336.	6.5	0
118	Bradykinin formation. Clinical Reviews in Allergy and Immunology, 1998, 16, 403-429.	6.5	47
119	Comparative studies of functional and binding assays for IgG anti-FcÏµRIÎ± (Î±-subunit) in chronic urticariaâ˜†â˜†â˜†â˜…â˜…... Journal of Allergy and Clinical Immunology, 1998, 101, 672-676.	2.9	159
120	The Intrinsic Coagulation/Kinin-Forming Cascade: Assembly in Plasma and Cell Surfaces in Inflammation. Advances in Immunology, 1997, 66, 225-272.	2.2	67
121	Chemokines in seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology, 1996, 97, 104-112.	2.9	73
122	Interaction of Plasma Contact Activation Factors with Vascular Endothelium. Endothelium: Journal of Endothelial Cell Research, 1995, 3, 99-111.	1.7	0
123	Effect of neurotropinÂ® on the activation of the plasma kallikrein-kinin system. Biochemical Pharmacology, 1992, 43, 1361-1369.	4.4	11
124	Quantification of human high molecular weight kininogen by immunoblotting with a monoclonal anti-light chain antibody. Journal of Immunological Methods, 1989, 119, 19-25.	1.4	17
125	Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum. Biochemical Pharmacology, 1989, 38, 993-1000.	4.4	67
126	The Mechanism of Degradation of Bradykinin (Lysyl-Bradykinin) in Human Serum. Advances in Experimental Medicine and Biology, 1989, 247A, 331-336.	1.6	6

#	Article	IF	Citations
127	Studies of the Cleavage of Human High Molecular Weight Kininogen by Purified Plasma and Tissue Kallikreins, and upon Contact Activation of Plasma. Advances in Experimental Medicine and Biology, 1989, 247B, 317-324.	1.6	2
128	Prevalence and Functional Role of Anti-IgE Autoantibodies in Urticarial Syndromes. Journal of Investigative Dermatology, 1988, 90, 213-217.	0.7	267
129	Assessment of kininases in rheumatic diseases and the effect of therapeutic agents. Arthritis and Rheumatism, 1987, 30, 138-145.	6.7	32
130	Studies of the digestion of bradykin, lys-bradykinin, and des-Arg9-bradykinin by angiotensin converting enzyme. Biochemical Pharmacology, 1986, 35, 1951-1956.	4.4	79
131	Studies of the digestion of bradykinin, lysyl bradykinin, and kinin-degradation products by carboxypeptidases A, B, and N. Biochemical Pharmacology, 1986, 35, 1957-1963.	4.4	58
132	Identification of a new physically induced urticaria: cold-induced cholinergic urticaria. Journal of Allergy and Clinical Immunology, 1981, 68, 438-441.	2.9	70
133	Idiopathic Cold Urticaria: In Vitro Demonstration of Histamine Release upon Challenge of Skin Biopsies. New England Journal of Medicine, 1981, 305, 1074-1077.	27.0	91
134	The Physical Urticarias. International Journal of Dermatology, 1980, 19, 417-435.	1.0	38
135	The mechanism by which the light chain of cleaved hmw-kininogen augments the activation of prekallikrein, factor XI and hageman factor. Thrombosis Research, 1980, 20, 173-189.	1.7	73
136	Autoactivatability of human Hageman factor (factor XII). Biochemical and Biophysical Research Communications, 1980, 92, 803-810.	2.1	60
137	In vivo studies of mediator release in cold urticaria and cholinergic urticaria. Journal of Allergy and Clinical Immunology, 1975, 55, 394-402.	2.9	230
138	SUBSTRATES OF HAGEMAN FACTOR. Journal of Experimental Medicine, 1974, 140, 1615-1630.	8.5	107
139	Inhibition by CaINH of Hageman Factor Fragment Activation of Coagulation, Fibrinolysis, and Kinin Generation. Journal of Clinical Investigation, 1973, 52, 1402-1409.	8.2	199
140	A PREALBUMIN ACTIVATOR OF PREKALLIKREIN. Journal of Experimental Medicine, 1971, 133, 696-712.	8.5	303
141	Hereditary Angioedema: Diagnosis, Pathogenesis, and Therapy. Current Treatment Options in Allergy, 0, , .	2.2	0